Glucotrol XL (Glipizide Extended Release) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 1, 2015 Category: Drugs & Pharmacology Source Type: news
glipizide/metformin (Metaglip)
Title: glipizide/metformin (Metaglip)Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 2/5/2015 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - February 5, 2015 Category: Endocrinology Source Type: news
glipizide/metformin (Metaglip)
Title: glipizide/metformin (Metaglip)Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 2/5/2015 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - February 5, 2015 Category: Drugs & Pharmacology Source Type: news
glipizide, Glipizide XL, Glucotrol, Glucotrol XL
Title: glipizide, Glipizide XL, Glucotrol, Glucotrol XLCategory: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 12/11/2014 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - December 11, 2014 Category: Endocrinology Source Type: news
glipizide, Glipizide XL, Glucotrol, Glucotrol XL
Title: glipizide, Glipizide XL, Glucotrol, Glucotrol XLCategory: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 12/11/2014 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - December 11, 2014 Category: Drugs & Pharmacology Source Type: news
JANUVIA (Sitagliptin) Compared With Sulfonylurea For Patients With Type 2 Diabetes And Mild Renal Impairment
Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced results from a post-hoc pooled analysis showing patients with type 2 diabetes and mild renal impairment treated with JANUVIA® (sitagliptin) 100 mg once-daily achieved similar blood sugar reductions as those treated with the sulfonylureas glipizide or glimepiride, with significantly fewer events of hypoglycemia (low blood sugar), and with weight loss instead of weight gain. Results were presented at the American Diabetes Association 73rd Scientific Sessions... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 25, 2013 Category: Consumer Health News Tags: Diabetes Source Type: news
New analysis shows that patients with Type 2 diabetes and mild renal impairment had similar improvement in blood sugar control and experienced less hypoglycemia with JANUVIA (sitagliptin) compared to sulfonylurea
(GCI Health NY) Merck, known as MSD outside the United States and Canada, today announced results from a post-hoc pooled analysis showing patients with Type 2 diabetes and mild renal impairment treated with JANUVIA (sitagliptin) 100 mg once-daily achieved similar blood sugar reductions as those treated with the sulfonylureas glipizide or glimepiride, with significantly fewer events of hypoglycemia, and with weight loss instead of weight gain. Results were presented at the American Diabetes Association 73rd Scientific Sessions. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 22, 2013 Category: Global & Universal Source Type: news
Metformin Superior to Glipizide in Diabetics With CADMetformin Superior to Glipizide in Diabetics With CAD
Over a median follow-up of five years, treatment with metformin reduced the primary composite end point of death from cardiovascular causes, death from any cause, nonfatal MI, nonfatal stroke, and arterial revascularization by 46% compared with glipizide. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 3, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news
Metformin superior to glipizide for reducing CVD events in diabetics with CAD
Over a median follow-up of five years, treatment with metformin reduced the primary composite end point of death from cardiovascular causes, death from any cause, nonfatal MI, nonfatal stroke, and arterial revascularization by 46% compared with glipizide. (Source: theHeart.org)
Source: theHeart.org - January 3, 2013 Category: Cardiology Source Type: news
Diabetics have fewer cardiovascular events with metformin than with glipizide
NEW YORK (Reuters Health) - Compared with glipizide, long-term therapy with metformin leads to a
reduction in major cardiovascular events in patients with type 2 diabetes, according to Chinese and US
researchers. (Source: Modern Medicine)
Source: Modern Medicine - January 1, 2013 Category: Journals (General) Source Type: news
